100% Remote Recruitment: Center for Neurscience and Regenerative Medicine
Bethesda, Maryland, 20817, United States
NCT Number: NCT06669780
The AMMO digital therapeutic (DTx) study will provide an online based program for participants with migraines after head injury to follow for 12 weeks. This study aims to see if using cognitive behavioral therapy aimed at military service members in an online self administered platform is effective therapy in the relief of migraines compared. The study will use a single blind online comparative program to test the effect.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Not applicable
Bethesda, Maryland, 20817, United States
The AMMO digital therapeutic (DTx) will be a novel intervention for PTH following concussive TBI, therefore this project is a pilot trial designed to test this new treatment. This pilot is a single-blind, randomized, controlled, interventional trial of current and former military personnel along with civilians with a history of concussive TBI and current PTH. The pilot trial will be conducted via online portal accessible by smartphone, tablet, or computer with remote interaction between participants and study staff. The pilot trial will include up to 100 participants randomized to either the active intervention or a comparison condition at a 1:1 ratio, and will provide preliminary data to determine the sample size of a future full clinical trial. Participants will complete a 12 week intervention period followed by a follow-up assessment 4 weeks after intervention is complete. Participants randomized to the comparison group will be provided access to the open label after end of 16 week follow-up.
In addition, updates to the DTx to improve usability and acceptability will be made if necessary based on feedback from the pilot trial, then applied to the final DTx used in a future, larger, clinical trial.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
o Headache is reported to have developed (or worsened) after one of the following*:
o The headache persists for >3 months after its onset (ICHD, 2013)
o Headache is reported to have developed (or worsened) after one of the following*:
o The headache persists for >3 months after its onset (ICHD, 2013)
Exclusion criteria
An online cognitive behavioral therapy program accessed through a online program.
Online activities not including CBT in the AMMO online program.
Time frame: 16 weeks
The HIT-6™ is a brief standardized headache screening tool and questionnaire, derived from the original 54-item Headache Impact Test. It has been found to have good psychometric properties in assessing headache impact among patients in clinical practice and research (Bjorner, Kosinski, & Ware, 2003; Kosinski et al., 2003).
Time frame: 12 weeks
Use of Headache Impact Test and number of headache days per month to compare arms. This data will identify any changes to sample size in future studies.
Time frame: 16 weeks
The PCL-5 is a self-report questionnaire designed to assess symptoms of PTSD (Blevins, Weathers, Davis, Witte, & Domino, 2015). The PCL-5 takes approximately 5-10 minutes to complete.
Time frame: 16 weeks
The TBI-QOL is a self-report questionnaire composed of 22 item banks (Tulsky et al., 2016). It was developed to measure multiple domains of life for patients living with TBI, including physical, mental, cognitive, and social. The TBI-QOL takes approximately 30 minutes to complete.
Time frame: 16 weeks
The PHQ-9 is a self-report assessment for depressive symptoms (Kroenke, Spitzer, & Williams, 2001). Each item is scored on a scale of 0 to 3 providing a summary score that ranges from 0 to 27, with higher scores representing more severe depression. On the PHQ-9 a total score <5 is considered minimal depression, and scores of 5 to 9, 10 to 14, 15 to 19, and 20 to 27 are considered mild, moderate, moderately severe, and severe depression, respectively.
Time frame: 16 weeks
The ISI is a self-report questionnaire designed to assess the presence and severity of primary insomnia sleep disorder and is empirically-validated in general and military populations (Bastien et al., 2001; Jenkins et al., 2015; Morin, Belleville, Belanger, & Ivers, 2011).
Time frame: 12 weeks
Adapted from the Mobile Application Rating Scale (MARS), the uMARS is a 26-item self-report questionnaire designed to assess the quality, functionality, and aesthetics of a mobile application and its information (Stoyanov, Hides, Kavanagh, & Wilson, 2016). There is an additional open-text question for further comments on the users' opinions of the application. The uMARS takes approximately 15 minutes to complete. This measure will be optional for participants to complete.
Time frame: 12 weeks
The mARM is an adaptation of a valid and reliable assessment of therapeutic alliance in face-to-face therapy (Berry, Salter, Morris, James, & Bucci, 2018). The 25-item questionnaire has been adjusted for use with digital health interventions, specifically for mental health. The mARM takes approximately 5 minutes to complete.
Time frame: 12 weeks
Brief questionnaire utilizing Likert Scales related to gathering user feedback on personal experience with ease and accessibility of app utilization.
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Single-Blind, Randomized, Controlled Pilot Trial of a Cognitive-Behavioral Therapy Digital Therapeutic Delivered Online for Post-Traumatic Headaches in Adults With History of Concussive Traumatic Brain Injury
Acronym: AMMO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04799015
Brain Diseases, Central Nervous System Diseases
The Bronx, New York, United States
View Trial DetailsNCT04098250
Brain Diseases, Central Nervous System Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT04369729
Brain Diseases, Central Nervous System Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT06132529
Brain Diseases, Central Nervous System Diseases
Phoenix, Arizona, United States
View Trial Details